15-Year Follow-Up begins for myeloma cell therapy patients
NCT ID NCT03741127
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows about 100 people with multiple myeloma who previously received an experimental cell therapy called P-BCMA-101. Researchers will monitor them for up to 15 years to see how safe and effective the treatment remains over time. A safety switch drug called rimiducid may also be given if needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
P-BCMA-101 (a type of cell therapy) and rimiducid (a safety switch activator)
What this could lead to
If successful, this could show that P-BCMA-101 provides lasting control of multiple myeloma with manageable long-term side effects.
What could go wrong
This is an early-phase follow-up study, not a large trial. It may not prove long-term benefit, and risks like delayed side effects or loss of effectiveness remain possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Johns Hopkins University
Baltimore, Maryland, 21205, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
University of California Davis
Davis, California, 95618, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
University of California, San Diego
San Diego, California, 92121, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Kansas Cancer Center
Westwood, Kansas, 66205, United States
-
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, 21201, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37203, United States
-
Wayne State - Karmanos Cancer Institute
Detroit, Michigan, 48201, United States